Alonso García-Ruiz

Alonso García-Ruiz

Auto-generated profile, based on publicly available information

Alonso García-Ruiz

Vall d'Hebron Institute of Oncology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Radiology
Verified
Journal Article
Closed access
MLMarta Ligero
Marta Ligero
AGAlonso Garcia-Ruiz
Alonso Garcia-Ruiz
CVCristina Viaplana
Cristina Viaplana
GVGuillermo Villacampa
Guillermo Villacampa
MRMaria V. Raciti
Maria V. Raciti
RPRaquel Perez-Lopez
Raquel Perez-Lopez
A CT-based radiomics signature, based on histogram, shape, and local-regional texture features, showed an association with immune response in advanced solid tumors. Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature to predict respons...

15 April 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
IMIgnacio Matos
Ignacio Matos
JMJuan Martin-Liberal
Juan Martin-Liberal
AGAlonso García-Ruiz
Alonso García-Ruiz
CHCinta Hierro
Cinta Hierro
MOMaria Ochoa de Olza
Maria Ochoa de Olza
EGElena Garralda
Elena Garralda
Purpose: Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR). However, there is still no consensus on how to evaluate this phenomenon. Patients and Methods: We investigated two independent cohorts of patients with advanced solid tumors treated in phase I trials with (i) programmed cell death 1 (PD-1)/PD-L1 antibodies in monotherapy or combination and (ii) targeted agents (TA) in unapproved indications. A Response Evaluation Criteria in Solid Tumors (RECIST) 1.1–based definition of hyperprogression was developed. The primary endpoint was the assessment of the rate of HPD in patients treated with ICIs or TAs using both criteria (RECIST and TGR) and the impact on overall survival (OS) in patients who achieved PD as best response. Results: Among 270 evaluable patients treated with PD-1/PD-L1 inhibitors, 29 PD-1/PD-L1–treated patients (10.7%) had HPD by RECIST definition. This group had a significantly lower OS (median of 5.23 months; 95% CI, 3.97–6.45) when compared with the non-HPD progressor group (median, 7.33 months; 95% CI, 4.53–10.12; HR = 1.73, 95% CI, 1.05–2.85; P = 0.04). In a subset of 221 evaluable patients, 14 (6.3%) were categorized as HPD using TGR criteria, differences in median OS (mOS) between this group (mOS 4.2 months; 95% IC, 2.07–6.33) and non-HPD progressors (n = 44) by TGR criteria (mOS 6.27 months; 95% CI, 3.88–8.67) were not statistically significant (HR 1.4, 95% IC, 0.70–2.77; P = 0.346). Among 239 evaluable patients treated with TAs, 26 (10.9%) were classified as having HPD by RECIST and 14 using TGR criteria in a subset of patients. No differences in OS were observed between HPD and non-HPD progressors treated with TAs. Conclusions: HPD measured by TGR or by RECIST was observed in both cohorts of patients; however, in our series, there was an impact on survival only in the immune-checkpoint inhibitor cohort when evaluated by RECIST. We propose a new way to capture HPD using RECIST criteria that is intuitive and easy to use in daily clinical practice.

1 March 2024 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
OPOlivia Prior
Olivia Prior
CMCarlos Macarro
Carlos Macarro
VGVictor Navarro Garcés
Victor Navarro Garcés
CMCamilo Monreal
Camilo Monreal
MLMarta Ligero
Marta Ligero
RPRaquel Perez-Lopez
Raquel Perez-Lopez
"Just Accepted" papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. Purpose To identify precise 3D radiomics features in CT images that enable computation of stable and biologically meaningful habitats with machine learning for cancer heterogeneity assessment. Materials and Methods This retrospective study included 2436 liver or lung lesions from 605 CT scans (November 2010-December 2021) in 318 patients with cancer (mean age, 64.5 years ± 10.1 [SD]; 185 male patients). 3D radiomics were computed from original and perturbed (simulated retest) images with different combinations of feature computation kernel radius (R) and bin size (B). The lower 95% confidence limit (LCL) of the intraclass correlation coefficient was used to measure repeatability and reproducibility. Precise features were identified by combining repeatability and reproducibility results (LCL ≥ 0.50). Habitats were obtained with Gaussian Mixture Models in original and perturbed data using precise radiomics features and compared with habitats obtained using all features. The Dice similarity coefficient (DSC) was used to assess habitat stability. Biologic correlates of CT habitats were explored in a case study, with a cohort of 13 patients with CT, multiparametric MRI (mpMRI) and tumor biopsies. Results 3D radiomics showed poor repeatability (median LCL[IQR] of 0.442 [0.312-0.516]) and poor reproducibility against R (0.44[0.33-0.526]) but excellent reproducibility against B (0.929[0.853-0.988]). Twentysix radiomics features were precise, differing in lung and liver lesions. Habitats obtained with precise features (DSC, 0.601 (0.494-0.712) and 0.651 (0.52-0.784) for lung and liver lesions, respectively) were more stable than those obtained with all features (DSC, 0.532 (0.424-0.637) and 0.587 (0.465-0.703), respectively; P < .001). In the case study, CT habitats correlated quantitatively and qualitatively, with heterogeneity observed in mpMRI habitats and histology. Conclusion Precise 3D radiomics features were identified on CT that enabled tumor heterogeneity assessment through stable tumor habitat computation. ©RSNA, 2024.

17 September 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
APAlbert Pons-Escoda
Albert Pons-Escoda
AGA. Garcia-Ruiz
A. Garcia-Ruiz
PNPablo Naval-Baudin
Pablo Naval-Baudin
MCM. Cos
M. Cos
NVNOEMI VIDAL
NOEMI VIDAL
CMC. Majos
C. Majos
BACKGROUND AND PURPOSE: DSC-PWI has demonstrated promising results in the presurgical diagnosis of brain tumors. While most studies analyze specific parameters derived from time-intensity curves, very few have directly analyzed the whole curves. The aims of this study were the following: 1) to design a new method of postprocessing time-intensity curves, which renders normalized curves, and 2) to test its feasibility and performance on the diagnosis of primary central nervous system lymphoma. MATERIALS AND METHODS: Diagnostic MR imaging of patients with histologically confirmed primary central nervous system lymphoma were retrospectively reviewed. Correlative cases of glioblastoma, anaplastic astrocytoma, metastasis, and meningioma, matched by date and number, were retrieved for comparison. Time-intensity curves of enhancing tumor and normal-appearing white matter were obtained for each case. Enhancing tumor curves were normalized relative to normal-appearing white matter. We performed pair-wise comparisons for primary central nervous system lymphoma against the other tumor type. The best discriminatory time points of the curves were obtained through a stepwise selection. Logistic binary regression was applied to obtain prediction models. The generated algorithms were applied in a test subset. RESULTS: A total of 233 patients were included in the study: 47 primary central nervous system lymphomas, 48 glioblastomas, 39 anaplastic astrocytomas, 49 metastases, and 50 meningiomas. The classifiers satisfactorily performed all bilateral comparisons in the test subset (primary central nervous system lymphoma versus glioblastoma, area under the curve = 0.96 and accuracy = 93%; versus anaplastic astrocytoma, 0.83 and 71%; versus metastases, 0.95 and 93%; versus meningioma, 0.93 and 96%). CONCLUSIONS: The proposed method for DSC-PWI time-intensity curve normalization renders comparable curves beyond technical and patient variability. Normalized time-intensity curves performed satisfactorily for the presurgical identification of primary central nervous system lymphoma.

6 October 2022 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
APAlbert Pons-Escoda
Albert Pons-Escoda
AGA. García-Ruíz
A. García-Ruíz
PNPablo Naval-Baudin
Pablo Naval-Baudin
FGF. Grussu
F. Grussu
MVM. Viveros
M. Viveros
CMC. Majós
C. Majós
BACKGROUND AND PURPOSE: Immunodeficiency-associated CNS lymphoma may occur in different clinical scenarios beyond AIDS. This subtype of CNS lymphoma is diffuse large B-cell and Epstein-Barr virus–positive. Its accurate presurgical diagnosis is often unfeasible because it appears as ring-enhancing lesions mimicking glioblastoma or metastasis. In this article, we describe clinicoradiologic features and test the performance of DSC-PWI metrics for presurgical identification. MATERIALS AND METHODS: Patients without AIDS with histologically confirmed diffuse large B-cell Epstein-Barr virus–positive primary CNS lymphoma (December 2010 to January 2022) and diagnostic MR imaging without onco-specific treatment were retrospectively studied. Clinical, demographic, and conventional imaging data were reviewed. Previously published DSC-PWI time-intensity curve analysis methodology, to presurgically identify primary CNS lymphoma, was used in this particular lymphoma subtype and compared with a prior cohort of 33 patients with Epstein-Barr virus–negative CNS lymphoma, 35 with glioblastoma, and 36 with metastasis data. Normalized curves were analyzed and compared on a point-by-point basis, and previously published classifiers were tested. The standard percentage of signal recovery and CBV values were also evaluated. RESULTS: Seven patients with Epstein-Barr virus–positive primary CNS lymphoma were included in the study. DSC-PWI normalized time-intensity curve analysis performed the best for presurgical identification of Epstein-Barr virus–positive CNS lymphoma (area under the receiver operating characteristic curve of 0.984 for glioblastoma and 0.898 for metastasis), followed by the percentage of signal recovery (0.833 and 0.873) and CBV (0.855 and 0.687). CONCLUSIONS: When a necrotic tumor is found in a potentially immunocompromised host, neuroradiologists should consider Epstein-Barr virus–positive CNS lymphoma. DSC-PWI could be very useful for presurgical characterization, with especially strong performance of normalized time-intensity curves.